OBJECTIVE: To investigate whether duration of obesity has an independent impact on insulin resistance. DESIGN: Case-control study. SUBJECTS: 30 non-diabetic obese subjects (age, 34 AE 2 y, body mass index (BMI), 33.5 AE 0.8 kg Á m 72 ) with a range (1±35 y) of self-reported duration of obesity, and 12 age-and gender-matched non-obese controls (BMI, 22.1 AE 0.6 kg Á m 72 ). MEASUREMENTS: Oral glucose tolerance (40 g Á m 72 ), insulin sensitivity (by the euglycaemic insulin clamp technique), and insulin secretion (as the product of post-hepatic insulin clearance and plasma insulin concentration). RESULTS: The obese group presented hyperinsulinaemia in the basal state and after glucose loading (insulin area 58 AE 5 vs 33 AE 3 nmol Á l 71 Á 2 h, P 0.005), insulin resistance (M value 37.4 AE 4.8 vs 50.6 AE 2.6 m mmol Á min
Introduction
Obesity is a state of insulin resistance involving whole-body glucose utilisation, 1 glucose oxidation and non-oxidative glucose disposal, 2 lipid metabolism 3 and insulin suppression of endogenous glucose release. 4 The hyperinsulinaemia of obesity is in part an adaptive response to insulin resistance and in part the result of insulin hypersecretion. 5 Obesity is a powerful risk factor for the development of non-insulin-dependent diabetes (NIDDM), 6±9 particularly when the excess fat is centrally accumulated. 10 Progression to impaired glucose tolerance or diabetes in the obese has been attributed to the insulin resistance itself, which antedates diabetes, 11 and to failure of b-cell function. However, the precise chronological sequence and the physiological interactions leading from obesity to diabetes are not fully understood. In a previous cross-sectional study involving obese patients with varying degrees of glucose intolerance, 12 progressively longer duration of obesity was associated with a fall in the insulin response to oral glucose, a rapid decline in non-oxidative disposal of oral glucose, and a rise in the fasting and postglucose plasma glucose concentrations. An implication of that study was that long-term obesity leads to NIDDM through a combination of worsening insulin resistance and failing insulin secretion. Neither insulin resistance nor insulin secretion were, however, measured. The purpose of the present study therefore was to relate insulin sensitivity and secretion to obesity duration in the presence of preserved glucose tolerance.
Materials and methods

Subjects
Thirty obese (body mass index (BMI) b 28 kg Á m 72 in men and b 27 kg Á m 72 in women) and twelve lean (BMI 25 kg Á m 72 in either men or women) subjects were studied. All subjects were normotensive according to the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC V) 13 (systolic blood pressure`140 mmHg and diastolic pressure`90 mmHg) and had normal glucose tolerance on the oral glucose tolerance test (OGTT) by the National Diabetes Data Group criteria.
14 None had had intercurrent diseases, lost weight or changed dietary habits during the six months prior to the study. None were taking any medication. The clinical characteristics are given in Table 1 . In the obese, duration of obesity was ascertained by careful questioning, and quantitated as number of years over which body weight had been within 10% of current body weight. The protocol was approved by the Institutional Review Board of the CNR Institute of Clinical Physiology, and all subjects gave informed consent before the study began.
Experimental protocol
In all study subjects, body composition was evaluated by electrical bioimpedance, 15 and the waist and hip circumferences were measured by the same physician. Each subject received an OGTT and a euglycaemic insulin clamp on different days approximately one week apart. For the OGTT, 40 g Á m 72 of glucose was ingested over 5 min, and venous blood was sampled at 30-min intervals for 2 h for plasma glucose and insulin measurements. The clamp study, which was carried out after an overnight (12±14 h) fast, consisted of 2 h of euglycaemic insulin infusion (at an insulin infusion rate of 7 pmol Á min 71 Á kg 71 ). 16 A polyethylene, 20-gauge catheter was inserted into an antecubital vein for the infusion of test substances, and another cannula was advanced into a wrist vein retrogradely. The hand was placed in a heated box (approx 60 C) for the sampling of arterialised blood. 17 Following this procedure, the patients rested for at least 30 min in the supine position. The following 2 h before the start of insulin infusion, constituted the basal period. During the basal period and the insulin clamp, endogenous glucose production (EGP) was determined with the use of the 6-3 H-glucose technique. 18 
Analytical procedures
Plasma glucose was measured by the glucose oxidase technique on a Beckman Glucose Analyzer (Beckman, Fullerton, CA). Plasma concentrations of insulin (InsKit, Sorin, Saluggia, Italy) were measured by radioimmunoassay. Plasma uric acid and triglycerides were assayed spectrophotometrically, in duplicate, on an Eris Analyser 6170 (Eppendorf Geratebau, Hamburg, Germany). Serum free fatty acids (FFA) were measured spectrophotometrically (Wako, Neuss, Germany).
Data analysis
Fat-free mass (FFM) was calculated as the difference between body weight and fat mass. Areas under OGTT time-concentration curves were calculated by the trapezium rule. Whole-body glucose utilisation (or the M value) was calculated from the infusion rate of exogenous glucose during the second hour of the insulin clamp, after correction for changes in glucose levels in a distribution volume of 250 ml Á kg
71
. The M value was normalised by kg of FFM (M ffm , in mmol Á min 71 Á kg FFM 71 ). Insulin sensitivity was expressed as either the M value or M ffm divided by the natural logarithm of steady-state plasma insulin concentration.
Under the steady-state conditions prevailing in the fasting state, the glucose rate of appearance (Ra) was calculated as the ratio between the tracer infusion rate and the basal glucose speci®c activity (SA). During insulin infusion, the estimation of changes in glucose Ra can be optimised by minimising the changes in plasma glucose SA. 19 To approximate a clamp of glucose SA, the basal tracer glucose infusion rate was halved every 15 min after the start of insulin infusion until 45 min into the clamp, when it was stopped. At the same time, the exogenous glucose infused during the clamp was enriched with 150 mCi of 6-3 H-glucose. This level of enrichment was chosen on the basis of previous experiments so as to match the steady-state plasma glucose SA prevailing during the basal state. 19 Non-steady state glucose Ra's were calculated from the isotopic data by a two-compartment model with an ad hoc computer program. 19 EGP was calculated as the difference between Ra and the exogenous glucose infusion rate.
Since exogenous hyperinsulinaemia suppresses fasting endogenous insulin release by approx 50%, 20 the post-hepatic insulin clearance rate was calculated as the ratio of insulin infusion rate to the difference between the steady-state plasma insulin concentration Obesity duration and insulin resistance in obesity E Muscelli et al and half the fasting insulin level. 21, 22 Fasting posthepatic insulin delivery rate was then obtained as the product of post-hepatic insulin clearance rate by the fasting plasma insulin concentration. Post-OGTT posthepatic insulin delivery was calculated as the product of insulin clearance and the OGTT area under insulin curve on the assumption that post-hepatic insulin clearance is unchanged during glucose absorption. 23 As previously shown, 24 the estimates of post-hepatic insulin release obtained with this method fall well within the range of values obtained by direct methods.
Statistical analysis
Data are given as mean AE s.e.m. The statistical signi®cance of differences between the means of the groups were tested with the use of the unpaired Student t test; differences in proportions were tested by w 2 analysis. Paired comparisons between basal and clamp values were performed by the paired t test. Factorial or repeated measure analysis of variance (ANOVA) was used when indicated. Simple and multiple linear regression analysis was carried out by standard techniques. A P value 0.05 was considered to be statistically signi®cant.
Results
The obese group was matched to the lean control group by age and gender. All indices of body mass and composition were higher in the obese than the lean group (Table 1) . Among the obese, the mean selfreported duration of obesity was 15.0 AE 1.7 y, ranging from 1±35 y.
Although all study subjects had normal glucose tolerance by diagnostic criteria, in the obese group the plasma glucose response to glucose ingestion was 15% higher than in the lean. The obese showed hyperinsulinaemia and insulin hypersecretion both in the fasting state and following oral glucose. Except for HDL-cholesterol, all serum lipids were higher in obese than in controls as were uric acid levels ( Table 2) .
The obese group was insulin resistant as compared to the lean controls by all indices of insulin-mediated glucose metabolism (Table 3) . Serum FFA levels did not differ between lean and obese subjects in the fasting state or during the clamp, but were signi®-cantly higher in the obese group during the OGTT (P 0.01, ANOVA for repeated measures). In the fasting state, EGP tended to be higher in obese than lean subjects, but the difference did not reach statistical signi®cance. During the clamp, EGP suppression was equivalent in the two groups. Differences between the obese and lean group were little changed by simultaneous gender adjustment.
In the pooled data, M ffm was inversely related to BMI, waist circumference and waist-to-hip ratio (WHR), fasting plasma insulin and plasma insulin response to glucose, serum triglyceride, HDL-cholesterol and uric acid levels, fasting EGP, and fasting and stimulated insulin delivery rate ( Figure 1 ) (P`0.04 or less for all). 
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When the obese subjects were strati®ed according to duration of obesity into three classes of similar age, gender, BMI, WHR, and percent fat mass, insulin sensitivity was signi®cantly better the longer the duration of obesity (Figure 2) . A similar trend was evident for glucose and insulin areas, and for fasting and stimulated insulin delivery (Table 4 ) but fell short of full statistical signi®cance.
The association of metabolic parameters with obesity duration was then examined after simultaneous adjustment by BMI, gender and age. As summarised in Table 5 , obesity itself (as the BMI) was independently associated with lower insulin sensitivity and higher glucose and insulin areas, fasting and stimulated insulin delivery rates, and higher serum triglyceride concentrations. For each variable, the BMI-independent effect of obesity duration was the opposite of that of BMI.
Discussion
In the present series, the obese subjects were hyperinsulinaemic and insulin resistant, and had increased insulin secretion, as evidenced by basal and glucosestimulated post-hepatic insulin delivery rates. Furthermore, they had signi®cantly higher fasting serum triglycerides, cholesterol and uric acid levels, as well as reduced suppression of plasma FFA during the OGTT. These metabolic abnormalities reproduce those previously described in obese groups.
24±26
Furthermore, the degree of insulin resistance was quantitatively related to amount and localisation of adipose excess, as well as to circulating lipid levels, endogenous glucose output and insulin hypersecretion. This is also in full accordance with expectation.
To cover a wide enough range, duration of obesity could only be assessed historically. Though patients are usually accurate in reporting their weight history, the actual duration of obesity is somewhat imprecise, particularly when weight loss and regain cycles have occurred. With these limitations, we found that both insulin sensitivity and insulin secretion, and, consequently, plasma insulin levels were signi®cantly better in subjects with longer duration of obesity in comparison with those who had gained weight more recently. More importantly, this association was independent of the current weight. In fact, multivariate analysis indicates that an increase in BMI of 10 units (approx 27 kg) had a negative (statistical) effect on insulin sensitivity (that is, a 30% decrease from the mean group value) that was balanced out by 20 y of overweight history. Because duration of obesity was tightly related to age of onset of obesity in a reciprocal fashion, the results equivalently indicate that insulin Figure 1 Inverse relationship between insulin sensitivity (as the M value on a euglycaemic insulin clamp) and insulin secretion (as the post-hepatic delivery rate of insulin following an oral glucose load). Obesity duration and insulin resistance in obesity E Muscelli et al sensitivity is better in individuals with early-onset obesity.
The current ®nding is in con¯ict with the notion that insulin resistance evolves in obesity as an adaptive mechanism to limit further weight gain, 27, 28 and that insulin resistance antedates diabetes. 11, 30 The contradiction is, however, only apparent. In fact, our obese subjects all had normal glucose tolerance; excluding patients with impaired glucose tolerance or overt NIDDM must have selected out subjects with more severe insulin resistance, particularly if their obesity was long lasting. Furthermore, though reduced energy expenditure is a risk factor for weight gain, 29 a high degree of insulin sensitivity rather than insulin resistance predicts development of obesity. 30 Therefore, our group was likely enriched with individuals in whom insulin sensitivity was high, especially in the longer duration subgroups, from which more insulin resistant subjects with glucose intolerance were likely to have been removed. Thus, our ®nding is compatible with the operation of a selection process, whereby the presence of insulin resistance channels overweight subjects through glucose intolerance to the development of diabetes. Those who stay glucose tolerant are protected by their good insulin sensitivity: the higher the insulin sensitivity the longer they can stay obese without progressing to NIDDM. Our data are of further interest in that they show that insulin secretion is consistently coupled with insulin sensitivity in a reverse fashion: the subjects with longer duration of obesity had lower insulin secretory rates than those with short-term obesity. Again, in the same subject a decline in insulin secretory capacity foreruns deterioration of glucose tolerance, 11, 31 but among obese subjects (as well as non-obese), preserved insulin sensitivity is associated with lower insulin secretion (Figure 1 ), precisely as expected on the basis of the feedback linking these two functions.
An alternative explanation of our ®nding is that, with duration of obesity some metabolic adaptation occurs. In longitudinal studies, weight gain is known to be associated with rising insulin levels, 33 and weight loss usually leads to some improvement in insulin sensitivity. 32, 34 Whether persistence of obesity is associated with changes in insulin resistance is, however, not known. Recent evidence suggests that with hypocaloric dieting, insulin resistance improves in proportion to the amount of weight lost whilst insulin hypersecretion persists. 25, 35 It is therefore likely that the interplay between primary insulin hypersecretion (i.e. that driven by central nervous stimuli) and secondary insulin hypersecretion (i.e. the part that is compensatory to insulin resistance) does evolve as a function of time. For example, as insulin secretion declines with age, our observation of lower insulin delivery rates in long-term obese subjects might stand for incipient exhaustion of b-cell function, heralding deterioration of glucose tolerance. However, metabolic adaptation can only be assessed by prospective examination, dif®cult as it may be to follow up non-diabetic subjects with stable overweight for long periods of time. *Entries are standardized regression coef®cients for the independent effect of the body mass index (BMI) and duration of obesity in a multiple regression model simultaneously adjusting for gender and age; values in parentheses indicate a P value b 0.05 and`0.1 for the partial regression coef®cients; TEV total explained variance; P P value for the full model.
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